Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Michael Driscoll, a director at Organogenesis Holdings Inc. (NASDAQ:ORGO), recently sold 25,000 shares of Class A common stock. The sale, which took place on March 4, 2025, was executed at a weighted-average price of $5.1014 per share, with transaction prices ranging from $5.00 to $5.33. This transaction resulted in a total sale value of $127,535. Following the sale, Driscoll retains ownership of 166,879 shares in the company.The stock, currently trading at $5.64, has shown remarkable momentum with a 128% gain over the past six months. According to InvestingPro analysis, ORGO appears undervalued at current levels, supported by strong financial health indicators including a healthy current ratio of 3.69 and manageable debt levels. InvestingPro has identified 15 additional investment tips for ORGO, available with a subscription, along with a comprehensive Pro Research Report that provides deep-dive analysis of the company’s fundamentals and growth prospects.
In other recent news, Organogenesis Holdings reported a strong fourth-quarter performance, exceeding analyst expectations with an earnings per share (EPS) of $0.04, compared to a forecast of -$0.01. The company’s revenue for the quarter reached $126.7 million, surpassing the anticipated $109.61 million and marking a 27% year-over-year increase. In light of these results, Cantor Fitzgerald analyst Ross Osborn raised the price target for Organogenesis to $6.00, maintaining an Overweight rating on the stock. Organogenesis has set a revenue guidance for 2025, projecting between $480 million and $535 million, which is above both Cantor Fitzgerald’s estimate and the FactSet consensus.
The company expects a challenging first half of 2025 but anticipates significant improvements following the implementation of new Medicare reimbursement policies in April. Organogenesis is positioned to benefit from these changes, as its products will remain eligible for Medicare reimbursement while many competitors’ products will not. The company’s strategic focus on clinical and real-world outcomes data, along with strong sales force retention, contributed to its robust financial performance. Organogenesis holds a strong cash position of $136.2 million with no outstanding debt, providing a solid foundation for future growth.
The company is also advancing its RENEW program, with expectations of completing clinical trials by the end of 2025. If approved, RENEW would be the only FDA-approved biologic injection for knee osteoarthritis, representing a significant opportunity for Organogenesis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.